Abpro Holdings, Inc. (ABPO) company profile
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
About Abpro
Biological Products, (No Diagnostic Substances), SIC 2836
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapeutics for patients with severe and life-threatening conditions. The company utilizes its proprietary antibody discovery and engineering platforms, DiversImmune and MultiMab, to design multi-specific antibody candidates primarily targeting immuno-oncology, ophthalmology, and infectious diseases. Its core pipeline includes ABP-102, a bispecific T-cell engager targeting HER2 and CD3 for solid tumors such as breast and gastric cancers, and ABP-201, a bispecific candidate designed to inhibit VEGF and ANG-2 to treat vascular diseases of the eye like wet age-related macular degeneration. The company pursues collaborative agreements and licensing partnerships with third-party biopharmaceutical developers, including Celltrion and Abpro Bio, to advance its programs.
The company operates corporate offices in Burlington, Massachusetts, where its principal executive facilities are located. Through territorial and global partnerships, Abpro engages in collaborative development agreements covering worldwide markets, including rights structured across Asia, the Middle East, and the Commonwealth of Independent States.
Summary of the business section of Abpro's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Abpro Holdings, Inc.
- Headquarters
- New York, NY
- Address
- 6 St Johns Lane, Floor 5 10013
- Phone
- (248) 890-7200
- Website
- abpro.co
- Employees
- 1, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Wolf & Company, P.C., Boston, MA
Stock & identifiers
- Ticker
- ABPO
- Other tickers
- ABPWW
- Former tickers
- ABP until Sep 1, 2026; ACAB until Nov 13, 2024
- Exchange
- OTC
- IPO date
- Jan 18, 2022
- Shares outstanding
- 6M, Aug 14, 2026
- Public float
- $9.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Nov 3, 2025
- SEC CIK
- 1893219
- CUSIP
- 000847202
- ISIN
- US0008472021
- FIGI
- BBG013X0S7F3
- Share class FIGI
- BBG013X0S889
- EIN
- 87-1013956
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jin Wook (Miles) Suk | CEO and Chairman, Director | 718,512 |
| Ian Chan | Chief Executive Officer, Director | 8,652,800 |
| Soo Young Lee | Director | – |
| Anthony D. Eisenberg | Director | – |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Total | vs. prior year |
|---|---|---|---|
| Ian Chan Former Chief Executive Officer | $521.75K | $521.75K | -32% |
| Robert Markelewicz Chief Medical Officer | $483.58K | $483.58K | -11% |
| Christian Zapf Former Senior Vice President of Corporate Development and Former General Counsel of Abpro Corporation (6) | $258.43K | $258.43K | -24% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jan 18, 2022
- Offer price
- $10.00
- Securities offered
- 26,100,000
- Gross proceeds
- $261.00M
- Exchange
- Nasdaq
- First trading day
- Mar 9, 2022
- First-day close
- $9.90-1.0%
- Lock-up ends (est.)
- Sep 5, 2022
“Per Unit Total Public offering price $ 10.00 $ 261,000,000 Underwriting discounts and commissions (1) $ 0.55 $ 14,355,000 Proceeds, before expenses, to us $ 9.45 $ 246,645,000 (1) $0.20 per unit, or $5,220,000 in the aggregate (or $6,003,000 if the underwriters’ over-allotment option is exercised in full), is paya”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 30, 2026, we had one full-time employee and two part-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?